In the latest edition of Citeline’s Scrip Asks series, Caszyme’s acting CEO, Dr. Giedrius Gasiunas, shares his perspective on where gene therapies are headed next.
Following the breakthrough of the first personalized CRISPR-based therapy in 2025, Giedrius expects individualized treatments to gain further momentum in 2026, supported with a continued expansion of the CRISPR–Cas toolbox and its adaptation across new therapeutic areas.
Read the full feature for insights from industry leaders and experts: https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation-NDREFKFVB5DZPAQLA5CIZHE7OI/